Jump to content

Glioblastoma: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Line 56: Line 56:


==Treatment==
==Treatment==
{{Main article|treatment of glioblastoma multiforme}}
It is very difficult to treat glioblastoma due to several complicating factors:<ref name = "pmid12672279">{{cite journal
It is very difficult to treat glioblastoma due to several complicating factors:<ref name = "pmid12672279">{{cite journal
| author = Lawson HC, Sampath P, Bohan E, ''et al.''
| author = Lawson HC, Sampath P, Bohan E, ''et al.''

Revision as of 11:30, 19 February 2010

Glioblastoma
SpecialtyNeuro-oncology Edit this on Wikidata
Image 1a. Coronal MRI with contrast of a glioblastoma WHO grade IV in a 15-year-old boy
Image 1b. Sagittal MRI with contrast of a glioblastoma WHO grade IV in a 15-year-old boy
Glioblastoma (histology slide)

Glioblastoma multiforme (GBM) is the most common and most aggressive type of primary brain tumor in humans, involving glial cells and accounting for 52% of all parenchymal brain tumor cases and 20% of all intracranial tumors. Despite being the most prevalent form of primary brain tumor, GBMs occur in only 2–3 cases per 100,000 people in Europe and North America. According to the WHO classification of the tumors of the central nervous system‎, the standard name for this brain tumor is "glioblastoma"; it presents two variants: giant cell glioblastoma and gliosarcoma. Glioblastomas are also an important brain tumor of the canine, and research is ongoing to use this as a model for developing treatments in humans.[1] Treatment can involve chemotherapy, radiation radiosurgery, corticosteroids, antiangiogenic therapy, and surgery. [2]

Glioblastoma has a very poor prognosis, despite multimodality treatment consisting of open craniotomy with surgical resection of as much of the tumor as possible, followed by concurrent or sequential chemoradiotherapy, antiangiogenic therapy with bevacizumab, gamma knife radiosurgery, and symptomatic care with corticosteroids. Other than the brainstem gliomas, it has the worst prognosis of any CNS malignancy.

Symptoms

Main article: Brain tumor

Although common symptoms of the disease include seizure, nausea and vomiting, headache, and hemiparesis, the single most prevalent symptom is a progressive memory, personality, or neurological deficit due to temporal and frontal lobe involvement. The kind of symptoms produced depends highly on the location of the tumor, more so than on its pathological properties. The tumor can start producing symptoms quickly, but occasionally is an asymptomatic condition until it reaches an enormous size.

Diagnosis

When viewed with MRI, glioblastomas often appear as ring-enhancing lesions. The appearance is not specific, however, as other lesions such as abscess, metastasis, tumefactive multiple sclerosis, and other entities may have a similar appearance.[3] Definitive diagnosis of a suspected GBM on CT or MRI requires a stereotactic biopsy or a craniotomy with tumor resection and pathologic confirmation. Because the tumor grade is based upon the most malignant portion of the tumor, biopsy or subtotal tumor resection can result in undergrading of the lesion.

Causes

GBM is more common in males, although the reason for this is not clear.[4] Most glioblastoma tumors appear to be sporadic, without any genetic predisposition. No links have been found between glioblastoma and smoking,[5] diet,[6] cellular phones,[7] or electromagnetic fields.[8] Recently, evidence for a viral cause has been discovered, possibly SV40[9] or cytomegalovirus.[10] There also appears to be a small link between ionizing radiation and glioblastoma.[11] Some also believe that there may be a link between polyvinyl chloride (which is commonly used in construction) and glioblastoma.[12] A recent link cited in the Lancet medical journal links brain cancer to lead exposure in the work place. [13]

Other risk factors include:[14]


Pathogenesis

Glioblastomas multiforme are characterized by the presence of small areas of necrotizing tissue that is surrounded by anaplastic cells (pseudopalisading necrosis). This characteristic, as well as the presence of hyperplastic blood vessels, differentiates the tumor from Grade 3 astrocytomas, which do not have these features.


GBM usually form in the cerebral white matter, grow quickly, and can become very large before producing symptoms. Some GBM form following degeneration of lower grade gliomas. These are called secondary GBM and are more common in younger patients. The tumor may extend into the meninges or ventricular wall, leading to high protein content in the cerebrospinal fluid (CSF) (> 100 mg/dL), as well as an occasional pleocytosis of 10 to 100 cells, mostly lymphocytes. Malignant cells carried in the CSF may spread (rarely) to the spinal cord or cause meningeal gliomatosis. However, metastasis of GBM beyond the central nervous system is extremely unusual. About 50% of GBM occupy more than one lobe of a hemisphere or are bilateral. Tumors of this type usually arise from the cerebrum and may rarely exhibit the classic infiltration across the corpus callosum, producing a butterfly (bilateral) glioma.

The tumor may take on a variety of appearances, depending on the amount of hemorrhage, necrosis, or its age. A CT scan will usually show a inhomogeneous mass with a hypodense center and a variable ring of enhancement surrounded by edema. Mass effect from the tumor and edema may compress the ventricles and cause hydrocephalus.

Cancer cells with stem cell-like properties have been found in glioblastomas (this may be a cause of their resistance to conventional treatments, and high re-occurrence rate).[15]

Treatment

It is very difficult to treat glioblastoma due to several complicating factors:[16]

  • The tumor cells are very resistant to other conventional therapies
  • The brain is susceptible to damage due to conventional therapy
  • The brain has a very limited capacity to repair itself
  • Many drugs cannot cross the blood-brain barrier to act on the tumor

Treatment of primary brain tumors and brain metastases consists of both symptomatic and palliative therapies.

Symptomatic therapy

Supportive treatment focuses on relieving symptoms and improving the patient’s neurologic function. The primary supportive agents are anticonvulsants and corticosteroids.

  • Historically, around 90% of patients with glioblastoma underwent anticonvulsant treatment, although it has been estimated that only approximately 40% of patients required this treatment. Recently, it has been recommended that neurosurgeons not administer anticonvulsants prophylactically, and should wait until a seizure occurs before prescribing this medication[17]. Those receiving phenytoin concurrent with radiation may have serious skin reactions such as erythema multiforme and Stevens-Johnson syndrome.
  • Corticosteroids, usually dexamethasone given 4 to 10 mg every 4 to 6 h, can reduce peritumoral edema (through rearrangement of the blood-brain barrier), diminishing mass effect and lowering intracranial pressure, with a decrease in headache or drowsiness.


Palliative therapy

Palliative treatment usually is conducted to improve quality of life and to achieve a longer survival time. It includes surgery, radiation therapy, and chemotherapy. A maximally feasible resection with maximal tumor-free margins is usually performed along with external beam radiation and chemotherapy. Gross total resection of tumor is associated with a better prognosis.

Surgery

Surgery is the first stage of treatment of glioblastoma. An average GBM tumor contains 1011 cells, which is on average reduced to 109 cells after surgery. It is used to take a section for a pathological diagnosis, to remove some of the symptoms of a large mass pressing against the brain, to remove disease before secondary resistance to radiotherapy and chemotherapy, and to prolong survival.

The greater the extent of tumor removal, the better. Removal of 98% or more of the tumor has been associated with a significantly longer healthier time than if less than 98% of the tumor is removed.[18] The chances of near-complete initial removal of the tumor can be greatly increased if the surgery is guided by a fluorescent dye known as 5-aminolevulinic acid.[19]

Radiotherapy

On average, radiotherapy after surgery can reduce the tumor size to 107 cells. Whole brain radiotherapy does not improve when compared to the more precise and targeted three-dimensional conformal radiotherapy.[20] A total radiation dose of 60–65 Gy has been found to be optimal for treatment.[21]

Boron neutron capture therapy has been tested as an alternative treatment for glioblastoma multiforme but is not in common use.

Chemotherapy

The standard of care for glioblastoma includes chemotherapy during and after radiotherapy. On average, chemotherapy after surgery and radiotherapy can initially reduce the tumor size to 106 cells. The use of temozolomide both during radiotherapy and for six months post radiotherapy results in a significant increase in median survival with minimal additional toxicity.[22] This treatment regime is now standard for most cases of glioblastoma where the patient is not enrolled in a clinical trial.[23][24] Temozolomide seems to work by sensitizing the tumor cells to radiation. [25]

The U.S. Food and Drug Administration approved Avastin (bevacizumab) to treat patients with glioblastoma at progression after standard therapy based on the results of 2 studies that showed Avastin reduced tumor size in some glioblastoma patients. In the first study, 28% of glioblastoma patients had tumor shrinkage, 38% survived for at least one year, and 43% survived for at least 6 months without their disease progressing. [26].

Immunotherapy

Relapse of glioblastoma is attributed to the recurrence and persistance of tumor stem cells.[27] In a small trial, a tumor B-cell hybridoma vaccine against tumor stem cells elicited a specific tumor immune reaction thus enhancing immune response to the disease.[28] Larger trials are in progress to further assess this approach to treating glioblastoma.

Recurrences

Long-term disease-free environment is possible, but the tumor usually reappears, often within 3 cm of the original site, and 10-20% may develop new lesions at distant sites. More extensive surgery and intense local treatment after recurrence has been associated with improvement.[29].

Prognosis

The median survival time from the time of diagnosis without any treatment is 3 months, but with treatment survival of 1-2 years is common. Increasing age (> 60 years of age) carries a worse prognostic risk. Death is usually due to cerebral edema or increased intracranial pressure. [30]

A good initial Karnofsky Performance Score (KPS), and MGMT methylation.[30] A DNA test can be conducted on glioblastomas to determine whether or not the promoter of the MGMT gene is methylated. Patients with a methylated MGMT promoter have been associated with significantly greater long-term benefit than patients with an unmethylated MGMT promoter.[31] This DNA characteristic is intrinsic to the patient and currently cannot be altered externally.

Long-term benefits have also been associated with those patients who receive surgery, radiotherapy, and temozolomide chemotherapy.[30] However, much remains unknown about why some patients survive longer with glioblastoma. Age of under 50 is linked to longer survival in glioblastoma multiforme, as is 98%+ resection and use of temozolomide chemotherapy and better Karnofsky performance scores.

UCLA Neuro-Oncology publishes real-time survival data for patients with this diagnosis. They are the only institution in the United States that shows how their patients are performing. They also show a listing of chemotherapy agents used to treat GBM tumors.

According to a 2003 study, glioblastoma multiforme prognosis can be divided into three subgroups dependent on KPS, the age of the patient, and treatment.[32]

RPA class Definition Historical Median Survival Time Historical 1-Year Survival Historical 3-Year Survival Historical 5-Year Survival
III Age < 50, KPS ≥ 90 17.1 months 70% 20% 14%
IV Age < 50, KPS < 90 11.2 months 46% 7% 4%
Age > 50, KPS ≥ 70, surgical removal with good neurologic function
V + VI Age ≥ 50, KPS ≥ 70, surgical removal with poor neurologic function 7.5 months 28% 1% 0%
Age ≥ 50, KPS ≥ 70, no surgical removal
Age ≥ 50, KPS < 70

References

Wikimedia Commons has media related to Glioblastoma.
  1. ^ Lipsitz D, Higgins RJ, Kortz GD; et al. (2003). "Glioblastoma multiforme: clinical findings, magnetic resonance imaging, and pathology in five dogs". Vet. Pathol. 40 (6): 659–69. doi:10.1354/vp.40-6-659. PMID 14608019. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  2. ^ Gina Kolata and Lawrence K. Altman, M.D. (August 27, 2009). "Kennedy Case Shows Progress and Obstacles in Cancer Fight". New York Times.
  3. ^ Smirniotopoulos JG, Murphy FM, Rushing EJ, Rees JH, Schroeder JW (2007). "Patterns of contrast enhancement in the brain and meninges". Radiographics. 27 (2): 525–51. doi:10.1148/rg.272065155. PMID 17374867.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  4. ^ Ohgaki H, Kleihues P (2005). "Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas". J Neuropathol Exp Neurol. 64 (6): 479–89. PMID 15977639.
  5. ^ Zheng, T, Cantor KP, Zhang Y; et al. (2001). "Risk of brain glioma not associated with cigarette smoking or use of other tobacco products in Iowa". Cancer Epidemiol Biomarkers Prev. 10 (4): 413–4. PMID 11319186. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  6. ^ Huncharek M, Kupelnick B, Wheeler L (2003). "Dietary cured meat and the risk of adult glioma: a meta-analysis of nine observational studies". J Environ Pathol Toxicol Oncol. 22 (2): 129–37. doi:10.1615/JEnvPathToxOncol.v22.i2.60. PMID 14533876.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  7. ^ Inskip PD, Tarone RE, Hatch EE; et al. (2001). "Cellular-telephone use and brain tumors". N Engl J Med. 344 (2): 79–86. doi:10.1056/NEJM200101113440201. PMID 11150357. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  8. ^ Savitz DA, Checkoway H, Loomis DP (1998). "Magnetic field exposure and neurodegenerative disease mortality among electric utility workers". Epidemiology. 9 (4): 398–404. doi:10.1097/00001648-199807000-00009. PMID 9647903.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  9. ^ Vilchez RA, Kozinetz CA, Arrington AS; et al. (2003). "Simian virus 40 in human cancers". Am J Med. 114 (8): 675–84. doi:10.1016/S0002-9343(03)00087-1. PMID 12798456. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  10. ^ "Target acquired", The Economist, May 29th, 2008
  11. ^ Cavenee L (2000). "High-grade gliomas with chromosome 1p loss". J Neurosurg. 92 (6): 1080–1. PMID 10839286.
  12. ^ http://www.brain-cancer-net.org/pvc-poly-vinyl-chloride.htm
  13. ^ Wijngaarden, Edwin van, (2006). "Brain cancer mortality and potential occupational exposure to lead: Findings from the National Longitudinal Mortality Study, 1979–1989". International Journal of Cancer. 119: 1136–44. doi:10.1002/ijc.21947.{{cite journal}}: CS1 maint: extra punctuation (link) CS1 maint: multiple names: authors list (link)
  14. ^ Glioblastoma multiforme at Mount Sinai
  15. ^ Murat A, Migliavacca E, Gorlia T; et al. (2008). "Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma". J. Clin. Oncol. 26 (18): 3015–24. doi:10.1200/JCO.2007.15.7164. PMID 18565887. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  16. ^ Lawson HC, Sampath P, Bohan E; et al. (2007). "Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience". Journal of Neuro-Oncology. 83 (1): 61–70. doi:10.1007/s11060-006-9303-1. PMID 17171441. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  17. ^ Stevens GHJ (2006). "Antiepileptic therapy in patients with central nervous system malignancies". Current Neurology and Neuroscience Reports. 6 (4): 311–318. doi:10.1007/s11910-006-0024-9. PMID 16822352.
  18. ^ Lacroix M, Abi-Said D, Fourney DR; et al. (2001). "A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis and extent of resection". J Neurosurg. 95 (2): 190–8. doi:10.3171/jns.2001.95.2.0190. PMID 11780887. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  19. ^ Stummer W, Pichimeier U, Meinel T; et al. (2006). "Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial". The Lancet Oncology. 7 (5): 392–401. doi:10.1016/S1470-2045(06)70665-9. PMID 16648043. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  20. ^ Showalter T, Andrel J, Andrews D; et al. (2007). "Multifocal Glioblastoma Multiforme: Prognostic Factors and Patterns of Progression". International Journal of Radiation OncologyBiologyPhysics,. 69 (3): 820–824. doi:10.1016/j.ijrobp.2007.03.045. PMID 17499453. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: extra punctuation (link) CS1 maint: multiple names: authors list (link)
  21. ^ Fulton DS, Urtasun RC, Scott-Brown, I; et al. (1992). "Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I–II dose response study". Journal of Neuro-Oncolog. 14 (1): 63–72. PMID 1335044. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  22. ^ Stupp R, Mason WP, van den Bent MJ; et al. (2005). "Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma". NEJM. 352 (10): 987–996. doi:10.1056/NEJMoa043330. PMID 15758009. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  23. ^ Mason WP, Mirimanoff RO, Stupp R; et al. (2006). "Radiotherapy with Concurrent and Adjuvant Temozolomide: A New Standard of Care for Glioblastoma Multiforme". Progress in Neurotherapeutics and Neuropsychopharmacology. 1: 37–52. doi:10.1017/S1748232105000054. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  24. ^ "Temozolomide Plus Radiation Helps Brain Cancer – National Cancer Institute". Retrieved 2007-09-15.
  25. ^ Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE (2007). "Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma". J. Neurooncol. 82 (1): 81–3. doi:10.1007/s11060-006-9241-y. PMID 16944309. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  26. ^ FDA Approves Drug for Treatment of Aggressive Brain Cancer [1]
  27. ^ Ghebah et al. Cancer Stem Cell Immunotherapy: the Right Bullet for the Right Target. Hematol Oncol Stem Cell Ther 2008;1:1-2 ["Hematology/Oncology and Stem Cell Therapy"
  28. ^ Moviglia GA, Carrizo AG, Varela G, et al. Preliminary report on tumor stem cell/B cell hybridoma vaccine for recurrent glioblastoma multiforme. Hematol Oncol Stem Cell Ther 2008;1:3-13. "Hematology/Oncology and Stem Cell Therapy"
  29. ^ Nieder C, Adama M, Mollsa M and Grosu AL (2006). "Therapeutic options for recurrent high-grade glioma in adult patients: Recent advances". Critical Reviews in Oncology/Hematology. 60 (3): 181–193. doi:10.1016/j.critrevonc.2006.06.007. PMID 16875833.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  30. ^ a b c Krex D, Klink B, Hartmann C; et al. (2007). "Long-term survival with glioblastoma multiforme". Brain. 130 (10): 2596–2606. doi:10.1093/brain/awm204. PMID 17785346. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  31. ^ Martinez R, Schackert G, Yaya-Tur R; et al. (2007). "Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme". Journal of Neuro-Oncology. 83 (1): 91–93. doi:10.1007/s11060-006-9292-0. PMID 17164975. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  32. ^ Shawl, EG, Seiferheld, W, Scott, C; et al. (2003). "Re-examining the radiation therapy oncology group (RTOG) recursive partitioning analysis (RPA) for glioblastoma multiforme (GBM) patients". International Journal of Radiation Oncology*Biology*Physics. 57 (2): S135–6. doi:10.1016/S0360-3016(03)00843-5. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Glioblastoma&oldid=345000918"